A Multicenter, Randomized, Single-Blind Crossover Study of the Safety and Tolerability of Two Adalimumab Formulations in Adult Subjects With Rheumatoid Arthritis.
Phase of Trial: Phase II
Latest Information Update: 11 Jun 2016
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors AbbVie
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Sep 2012 Planned End Date changed from 1 Sep 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 01 May 2012 Planned end date changed from 1 Oct 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.